Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Bispecific antibodies: a mechanistic review of the pipeline.

Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI.

Nat Rev Drug Discov. 2019 Aug;18(8):585-608. doi: 10.1038/s41573-019-0028-1. Review.

PMID:
31175342
2.

CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory.

Benonisson H, Altıntaş I, Sluijter M, Verploegen S, Labrijn AF, Schuurhuis DH, Houtkamp MA, Verbeek JS, Schuurman J, van Hall T.

Mol Cancer Ther. 2019 Feb;18(2):312-322. doi: 10.1158/1535-7163.MCT-18-0679. Epub 2018 Oct 31.

PMID:
30381448
3.

Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecific immunoglobulin G1 antibodies.

Goulet DR, Orcutt SJ, Zwolak A, Rispens T, Labrijn AF, de Jong RN, Atkins WM, Chiu ML.

J Biol Chem. 2018 Jan 12;293(2):651-661. doi: 10.1074/jbc.RA117.000303. Epub 2017 Nov 17.

4.

Cysteine-SILAC Mass Spectrometry Enabling the Identification and Quantitation of Scrambled Interchain Disulfide Bonds: Preservation of Native Heavy-Light Chain Pairing in Bispecific IgGs Generated by Controlled Fab-arm Exchange.

van den Bremer ETJ, Labrijn AF, van den Boogaard R, Priem P, Scheffler K, Melis JPM, Schuurman J, Parren PWHI, de Jong RN.

Anal Chem. 2017 Oct 17;89(20):10873-10882. doi: 10.1021/acs.analchem.7b02543. Epub 2017 Oct 2.

PMID:
28922593
5.

Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models.

Labrijn AF, Meesters JI, Bunce M, Armstrong AA, Somani S, Nesspor TC, Chiu ML, Altintaş I, Verploegen S, Schuurman J, Parren PWHI.

Sci Rep. 2017 May 30;7(1):2476. doi: 10.1038/s41598-017-02823-9.

6.

Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.

Losen M, Labrijn AF, van Kranen-Mastenbroek VH, Janmaat ML, Haanstra KG, Beurskens FJ, Vink T, Jonker M, 't Hart BA, Mané-Damas M, Molenaar PC, Martinez-Martinez P, van der Esch E, Schuurman J, de Baets MH, Parren PWHI.

Sci Rep. 2017 Apr 20;7(1):992. doi: 10.1038/s41598-017-01019-5.

7.

Hitting Ebola, to the power of two.

Labrijn AF, Parren PW.

Science. 2016 Oct 21;354(6310):284-285. No abstract available.

PMID:
27846516
8.

Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen.

Wang G, de Jong RN, van den Bremer ET, Beurskens FJ, Labrijn AF, Ugurlar D, Gros P, Schuurman J, Parren PW, Heck AJ.

Mol Cell. 2016 Jul 7;63(1):135-45. doi: 10.1016/j.molcel.2016.05.016. Epub 2016 Jun 16.

9.

Controlled Fab-arm exchange for the generation of stable bispecific IgG1.

Labrijn AF, Meesters JI, Priem P, de Jong RN, van den Bremer ET, van Kampen MD, Gerritsen AF, Schuurman J, Parren PW.

Nat Protoc. 2014 Oct;9(10):2450-63. doi: 10.1038/nprot.2014.169. Epub 2014 Sep 25.

PMID:
25255089
10.

Opening the door to innovation.

Schuurman J, Graus YF, Labrijn AF, Ruuls S, Parren PW.

MAbs. 2014 Jul-Aug;6(4):812-9. doi: 10.4161/mabs.29004. Epub 2014 Apr 24. Review.

11.

Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches.

Gramer MJ, van den Bremer ET, van Kampen MD, Kundu A, Kopfmann P, Etter E, Stinehelfer D, Long J, Lannom T, Noordergraaf EH, Gerritsen J, Labrijn AF, Schuurman J, van Berkel PH, Parren PW.

MAbs. 2013 Nov-Dec;5(6):962-73. doi: 10.4161/mabs.26233. Epub 2013 Aug 22.

12.

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW.

Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5145-50. doi: 10.1073/pnas.1220145110. Epub 2013 Mar 11.

13.

Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG.

Rose RJ, van Berkel PH, van den Bremer ET, Labrijn AF, Vink T, Schuurman J, Heck AJ, Parren PW.

MAbs. 2013 Mar-Apr;5(2):219-28. doi: 10.4161/mabs.23532. Epub 2013 Feb 13.

14.

Fab-arm exchange: what's in a name?

Schuurman J, Labrijn AF, Parren PW.

MAbs. 2012 Nov-Dec;4(6):636. doi: 10.4161/mabs.22075. Epub 2012 Sep 6. No abstract available.

15.

Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry.

Rose RJ, Labrijn AF, van den Bremer ET, Loverix S, Lasters I, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW, Heck AJ.

Structure. 2011 Sep 7;19(9):1274-82. doi: 10.1016/j.str.2011.06.016.

16.

Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength.

Labrijn AF, Rispens T, Meesters J, Rose RJ, den Bleker TH, Loverix S, van den Bremer ET, Neijssen J, Vink T, Lasters I, Aalberse RC, Heck AJ, van de Winkel JG, Schuurman J, Parren PW.

J Immunol. 2011 Sep 15;187(6):3238-46. doi: 10.4049/jimmunol.1003336. Epub 2011 Aug 12.

17.

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo.

Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, van de Winkel JG, Parren PW.

Nat Biotechnol. 2009 Aug;27(8):767-71. doi: 10.1038/nbt.1553. Epub 2009 Jul 20.

PMID:
19620983
18.

When binding is enough: nonactivating antibody formats.

Labrijn AF, Aalberse RC, Schuurman J.

Curr Opin Immunol. 2008 Aug;20(4):479-85. doi: 10.1016/j.coi.2008.05.010. Epub 2008 Jul 9. Review.

PMID:
18577454
19.

In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation.

Seshasayee D, Lee WP, Zhou M, Shu J, Suto E, Zhang J, Diehl L, Austin CD, Meng YG, Tan M, Bullens SL, Seeber S, Fuentes ME, Labrijn AF, Graus YM, Miller LA, Schelegle ES, Hyde DM, Wu LC, Hymowitz SG, Martin F.

J Clin Invest. 2007 Dec;117(12):3868-78.

20.
21.

Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.

Darbha R, Phogat S, Labrijn AF, Shu Y, Gu Y, Andrykovitch M, Zhang MY, Pantophlet R, Martin L, Vita C, Burton DR, Dimitrov DS, Ji X.

Biochemistry. 2004 Feb 17;43(6):1410-7.

PMID:
14769016
22.

Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning.

Zhang MY, Shu Y, Rudolph D, Prabakaran P, Labrijn AF, Zwick MB, Lal RB, Dimitrov DS.

J Mol Biol. 2004 Jan 2;335(1):209-19.

PMID:
14659751
23.

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Vivona V, Grundner C, Huang CC, Venturi M, Petropoulos CJ, Wrin T, Dimitrov DS, Robinson J, Kwong PD, Wyatt RT, Sodroski J, Burton DR.

J Virol. 2003 Oct;77(19):10557-65.

24.
25.

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.

Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, Dimitrov DS.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6913-8. Epub 2002 May 7.

26.

Novel strategy for the selection of human recombinant Fab fragments to membrane proteins from a phage-display library.

Labrijn AF, Koppelman MH, Verhagen J, Brouwer MC, Schuitemaker H, Hack CE, Huisman HG.

J Immunol Methods. 2002 Mar 1;261(1-2):37-48.

PMID:
11861064
27.

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW.

J Virol. 2001 Nov;75(22):10892-905.

28.

Recognition properties of V3-specific antibodies to V3 loop peptides derived from HIV-1 gp120 presented in multiple conformations.

Huisman JG, Carotenuto A, Labrijn AF, Papavoine CH, Laman JD, Schellekens MM, Koppelman MH, Hilbers CW.

Biochemistry. 2000 Sep 5;39(35):10866-76.

PMID:
10978173
29.

In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope.

Parren PW, Fisicaro P, Labrijn AF, Binley JM, Yang WP, Ditzel HJ, Barbas CF 3rd, Burton DR.

J Virol. 1996 Dec;70(12):9046-50.

Supplemental Content

Loading ...
Support Center